Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Alnylam Pharmaceuticals Stock Quote

Alnylam Pharmaceuticals (NASDAQ: ALNY)

Price as of July 25, 2024, 3:39 p.m. ET

Alnylam Pharmaceuticals Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
ALNY +22.24% +209.69% +25.37% +3,835%
S&P +18.82% +79.36% +12.39% +384%

Alnylam Pharmaceuticals Company Info

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

News & Analysis

The Fool has written over 200 articles on Alnylam Pharmaceuticals.


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.